At the recent San Antonio Breast Cancer Symposium (SABCS), the clinical evaluation of pertuzumab and trastuzumab (CLEOPATRA) clinical trial results were presented by Dr José Baselga (Massachusetts General Hospital).
This study combined two anti human epidermal growth factor receptor 2 (HER2) monoclonal antibodies, trastuzumab and pertuzumab with docetaxel.
Results showed a median progression-free survival of 18.5 months in the pertuzumab plus trastuzumab plus docetaxel group as compared to 12.4 months in the control group that received placebo plus trastuzumab plus docetaxel.
In other words the addition of pertuzumab improved PFS by 6.1 months. As Sally Church writing on Pharma Strategy Blog noted in her second update from SABCS, this is “another stunning six month leap in survival.”
The two monoclonal antibodies have different mechanisms of action and as Sally discusses in her post,
“the idea behind combining pertuzumab and trastuzumab upfront is to enable a more comprehensive shutdown of the HER2 pathway and delay the resistance setting in.”
You can read more on Pharma Strategy Blog. There was a lot of new data presented at the San Antonio Breast Cancer Symposium this year, and seeing the improvement in patient survival from BOLERO-2 and CLEOPATRA is what all those involved in the industry live for.
Sally poignantly describes this in her summary of SABCS:
“This year’s San Antonio Breast Cancer Symposium was very uplifting and one of the more exciting meetings of the last five years.”
Please contact us If you are interested in learning more about the breast cancer market and the impact new products in development such as the antibody drug conjugate T-DM1 and HDAC inhibitor, entinostat may have.